Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 5, 2009

AstraZeneca Taps Jubilant for Discovery Work

  • Jubilant Biosys entered a research collaboration agreement with AstraZeneca, which will initially focus on the neuroscience area. Under the shared risk-reward collaboration, Jubilant is tasked with delivering a steady stream of discovery programs to AstraZeneca.

    The goal is to provide AstraZeneca with four to six preclinical programs, which could lead to one to two preclinical candidates per year for the initial five-year period, according to Seema Ahuja, media spokesperson for Jubilant.

    AstraZeneca will have global ownership of the compounds developed under the collaboration. Jubilant will be eligible to receive research funding, spanning an initial five-year period. In addition, AstraZeneca will also pay success-based development milestones as well as royalties on global commercialization of any compound.

    Jubilant Biosys provides integrated drug discovery and development solutions with a facility in Bangalore. The center houses over 300 scientists specializing in disciplines ranging from discovery biology, toxicology, and information technology.


    Related AstraZeneca Deals:

    Palatin and AstraZeneca Expand Partnership in Obesity Drug R&D (Dec. 9, 2008)
    AstraZeneca and Singapore Institutions Ally to Develop Drugs for Liver Cancer (Aug. 15, 2008)
    AstraZeneca Taps Cenix for RNAi Drug Discovery (Mar. 19, 2008)
    Silence Therapeutics Could Earn $400M in siRNA Partnership with AstraZeneca (July 6, 2007)
    BioFocus DPI and AstraZeneca Sign Second Discovery Transaction (Apr. 19, 2007)

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: [email protected] An error has occurred. Please contact Customer Service at [email protected]
  • You’re all set! Thank you for subscribing to GEN Highlights.